BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely
Active, not recruiting
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 13779
- Registration Number
- NCT05202301
- Locations
- 🇺🇸
Bayer, Whippany, New Jersey, United States
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
Phase 3
Recruiting
- Conditions
- Chronic Kidney DiseaseProteinuria
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 219
- Registration Number
- NCT05196035
- Locations
- 🇩🇰
Rigshospitalet - Børn og Unge, Copenhagen, Denmark
🇭🇺Pecsi Tudomanyegyetem Klinikai Kozpont, Pecs, Hungary
🇭🇺SZTE ÁOK Szent Györgyi Albert Klinikai Kozpont, Szeged, Hungary
A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice
Completed
- Conditions
- Solid Tumors Harboring NTRK Fusion
- Interventions
- Drug: Larotrectinib(Vitrakvi, BAY2757556)Drug: Data on other treatments
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 368
- Registration Number
- NCT05192642
- Locations
- 🇺🇸
Bayer, Whippany, New Jersey, United States
A Study Called Champion-HMB to Learn More About Females With Heavy Menstrual Bleeding and Available Treatments to Enable Earlier Diagnosis and to Predict Courses of Treatment
Completed
- Conditions
- Heavy Menstrual Bleeding
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 99999
- Registration Number
- NCT05176496
- Locations
- 🇩🇪
Bayer, Berlin, Germany
Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer
Phase 2
Active, not recruiting
- Conditions
- Prostate Cancer
- Interventions
- Drug: Androgen deprivation therapy (ADT)
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 70
- Registration Number
- NCT05171387
- Locations
- 🇨🇳
Many Locations, Multiple Locations, China
A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)
Completed
- Conditions
- Treatment of Venous Thromboembolism in Cancer Patients
- Interventions
- Drug: Low molecular weight heparin (LMWH)Drug: other NOACs
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 5737
- Registration Number
- NCT05150938
- Locations
- 🇸🇪
Swedish registries, Multiple Locations, Many Locations, Sweden
A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer
Completed
- Conditions
- Metastatic Castration-sensitive Prostate Cancer
- Interventions
- Drug: ADT (Eligard®*) with or without treatment intensification
- First Posted Date
- 2021-12-08
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 960
- Registration Number
- NCT05149131
- Locations
- 🇨🇦
Databases, Multiple Locations, Alberta, Canada
A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood
Phase 3
Active, not recruiting
- Conditions
- Prophylaxis of BleedingHemophilia ATreatment of BleedingChildren
- Interventions
- Biological: Damoctocog alfa pegol (Jivi, BAY94-9027)
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 35
- Registration Number
- NCT05147662
- Locations
- 🇨🇦
Alberta Children's Hospital - Hematology / Oncology / Blood and Marrow Transplant Clinic, Calgary, Alberta, Canada
🇺🇸Arnold Palmer Hospital for Children, Orlando, Florida, United States
🇦🇷Hospital de Niños Sor María Ludovica, La Plata, Buenos Aires, Argentina
A Study to Gather Information About Rivaroxaban in Patients in the United Kingdom Who Have Cancer and Thrombosis (OSCAR-UK)
Completed
- Conditions
- Treatment of Venous Thromboembolism in Cancer Patients
- Interventions
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2601
- Registration Number
- NCT05112666
- Locations
- 🇬🇧
Many locations, Multiple Locations, United Kingdom
A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)
Phase 3
Completed
- Conditions
- Vasomotor Symptoms Associated With MenopauseHot Flashes
- Interventions
- Drug: Elinzanetant (BAY3427080)Drug: Placebo
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 400
- Registration Number
- NCT05099159
- Locations
- 🇺🇸
Unified Women's Clinical Research - Raleigh, Raleigh, North Carolina, United States
🇺🇸Clinical Research of West Florida, Inc., Clearwater, Florida, United States
🇺🇸Metro Jackson OB-GYN, Jackson, Mississippi, United States
© Copyright 2025. All Rights Reserved by MedPath